<?xml version="1.0" encoding="UTF-8"?>
<ref id="B69-pharmaceuticals-13-00096">
 <label>69.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Shi</surname>
    <given-names>J.G.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Emm</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Scherle</surname>
    <given-names>P.A.</given-names>
   </name>
   <name>
    <surname>Lo</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Punwani</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Williams</surname>
    <given-names>W.V.</given-names>
   </name>
   <name>
    <surname>Yeleswaram</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers</article-title>
  <source>J. Clin. Pharmacol.</source>
  <year>2014</year>
  <volume>54</volume>
  <fpage>1354</fpage>
  <lpage>1361</lpage>
  <pub-id pub-id-type="doi">10.1002/jcph.354</pub-id>
  <pub-id pub-id-type="pmid">24965573</pub-id>
 </element-citation>
</ref>
